Relmada outlines NDV-01 IND submission by year-end 2026 with cash runway through 2029

Rekor outlines operating model for profitability at approximately $50M annual revenue while prioritizing December note refinancing

Journey Medical anticipates Emrosi addition to a national plan with over 25M lives beginning 2027

Lulu’s outlines $5M annualized savings amid revised 2026 outlook and financing talks

Codexis reiterates $72M-$76M 2026 revenue outlook while extending cash runway through 2028